With the recent developments in the atopic dermatitis (AD) market, the field is becoming more competitive as novel therapies are soon anticipated to enter the market. This evolution may benefit AD ...

The facility is set to produce DS for biopharmaceuticals, leveraging the company's protein engineering and antibody ...

As work progresses on an up-and-coming biologics plant in North Carolina, specialty pharma company Kyowa Kirin has completed ...

Amgen today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or ...